Providing genomic analysis to everybody. SeqOne is a company focused on developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The company's vision is to develop a genomic analysis system that dramatically reduces the cost and resources needed to provide accurate genomic analysis. Our aim is to make genetic testing easier and more accessible in order to accelerate the adoption of personalized medicine. SeqOne’s platform makes it possible to efficiently analyze "high resolution" next generation sequencing (NGS) data, providing a complete list of all genetic variants and prioritizing them in order of relevance. The platform uses a proprietary machine learning-based variant prioritization engine designed to identify variants that are medically relevant to each specific patient. SeqOne bioinformatics (genomic analysis algorithms) are organized by applications, which provide accurate answers to medical questions that influence patient treatment, in both constitutional and somatic pathologies. SeqOne offers applications to analyze a single-patient or an entire family to diagnose hereditary family disorders, detecting complex events such as large structural modifications or transposable elements. In the field of somatic cancer, applications can analyze tumor-only, compare healthy versus tumoral samples, or hematological cancers identifying relevant variants, such as somatic CNV, TMB, MSI, or fusion genes, as well as suggest therapeutic options. The SeqOne platform addresses the operational challenges of performing NGS analysis at scale, including secure data storage, management of process quality, and traceability needed for certification. We adopt a unique approach to process quality control that addresses ongoing process monitoring as well as changes to upstream lab procedures.
Location: France, Occitania, Montpellier
Employees: 51-200
Total raised: $22.64M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 27.03.2021 | Elaia Part... | elaia.com |
| 12.03.2022 | Korys | korys.be |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.01.2022 | Series A | $22.64M | - |
Mentions in press and media 15
| Date | Title | Description |
| 16.02.2026 | Elaia Secures €120 Million for New European B2B Tech Fund, Targets €300 Million | Elaia announces a €120 million first close for its Digital Venture Fund V (DV5). The fund targets €300 million. It will fuel European B2B technology startups. Investments span pre-Seed to Series B. Ticket sizes range from €1 million to €15 ... |
| 11.02.2026 | French VC Elaia reaches €120 million first close for new multi-stage B2B technology fund | Paris-based VC firm Elaia has announced the first close of its fifth Digital Venture Fund (DV5) at €120 million, with ambitions to scale to €300 million, to back European B2B technology startups from pre-Seed to Series B, deploying ticket s... |
| 11.02.2026 | Elaia’s Digital Venture Fund V reaches €120M at first close | Elaia has announced a first close of its fifth Digital Venture Fund (DV5) at €120 million. The fund will focus on investing in European B2B technology companies with strong intellectual property foundations, spanning both foundational infra... |
| 05.09.2025 | Netomnia secures €346.2M, 0TO9's plan to build 1,000 fintechs by 2045, and August tech funding cooldown | This week, we tracked more than 60 tech funding deals worth over €1.3 billion, and over 25 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most ... |
| 02.09.2025 | SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine | Strategic acquisition of UK genomics leader Congenica reinforces SeqOne market position and footprint - servicing over 160 labs in 30+ countries ROME, ITALY, September 2, 2025 /EINPresswire.com/ -- SeqOne, a pioneer in AI-driven genomic ana... |
| 02.09.2025 | Montpellier-based SeqOne acquires Cambridge-based Congenica to create a global leader in AI-powered genomic medicine | SeqOne, a French innovator in AI-driven genomic analysis, today announced it has entered into a definitive agreement to acquire Congenica, the UK company spun out of the Wellcome Sanger Institute. The acquisition is set to create the “large... |
| 02.09.2025 | SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine | SeqOne, a pioneer in AI-driven genomic analysis, has entered into a definitive agreement to acquire Congenica, the UK company spun out of the Wellcome Sanger Institute. The acquisition creates the largest global ‘software pure player’ in th... |
| 02.09.2025 | Dcluttr Raises Pre-Seed Funding Round | Dcluttr, a Bengaluru, Karnataka, India-based AI copilot for growth marketing, raised an undisclosed amount in Pre-Seed funding. The round was led by Campus Fund. The company intends to use the funds for technology development, product desig... |
| 02.09.2025 | SeqOne Acquires Congenica | SeqOne, a Montpellier, France-based AI-driven genomic analysis company, acquired Congenica, a Cambridge, UK-based digital health company. The amount of the deal was not disclosed. The combined entity will have expanded global footprint: Ena... |
| 26.10.2023 | SeqOne Genomics appoints Martin Dubuc, Senior Pharmaceutical and Digital Health executive to its Board of Directors | Martin Dubuc, Boardmember SeqOne Genomics M. Dubuc will strengthen the Board’s capabilities in the fields of personalized medicine and companion diagnostics Martin’s shrewd business acumen and knowledge of the pharma industry will continue ... |
Show more